Trial Profile
A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jan 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin detemir (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 24 May 2012 Official title amended as reported by ClinicalTrials.gov.
- 07 Mar 2012 Planned number of patients changed from 1569 to NULL.
- 14 May 2008 New trial record.